Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi – Professor of Medicine at Memorial Sloan Kettering Cancer Center.
![DESTINY-Breast04 Study Discussion with Dr. Shanu Modi - Onc Brothers](https://oncbrothers.com/wp-content/uploads/2022/12/Untitled-1200x526.png)